spotlights
thinking
news
Going one step further, this report addresses why most leaders fail to effectively solve for this problem.
SpringTide was major investor in PathologyWatch’s $3M Seed round in early 2019, and took a board seat at that time. Read here to learn more!
We had the chance to sit with Dr. Larson to learn more about where she draws inspiration: her upbringing, her colleagues, and her clients.
Wellsheet’s mission is to reduce EHR-induced clinician burnout with a measurable ROI that makes clinicians’ day-to-day practice responsibilities easier so that they can focus on what’s most important: delivering the best care possible to patients.
After seeing a good friend battle misdiagnosed health issues that eventually led to depression, job loss, and deportation before finally being correctly diagnosed with hypothyroidism, Guillaume Cohen-Skalli got on Google and learned everything he could about the disease. Then he did what any good venture capitalist would do: He quit his own job and got to work addressing the problem by cofounding Paloma Health, an online company singularly centered on treating hypothyroidism.
The Paloma Health founder and CEO is seeking to provide better access to care and better quality of care by combining lifestyle changes with medical care and chronic condition management tools. “It’s the combination of those three approaches together in one full-stack solution that is revolutionizing hypothyroidism care,” he says.
Intellihealth CEO’s mission is to democratize and scale access to effective obesity medicine for as many people as possible.
Dr. Niamh O’Hara is the cofounder and CEO of Biotia, a health-tech company located in New York City that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. The company’s mission is to bring its advanced technology from the bench to the bedside for improved patient outcomes.
Biotia was born out of its founders’ desire to improve the ability of hospitals to diagnose and treat infectious disease. They were familiar with technology available in their own research experience but weren’t seeing hospitals take advantage of it in a way that benefitted individual patients. “Biotia’s values are really related to our mission, which is fighting infectious diseases powered by genomics and AI while building a leading microbial sequence database,” Dr. O’Hara says. “Our values are centered on improving patient care and protecting humanity from pandemics.”
SpringTide was major investor in PathologyWatch’s $3M Seed round in early 2019, and took a board seat at that time. Read here to learn more!